
Quarterly report 2025-Q3
added 11-05-2025
USANA Health Sciences Financial Statements 2011-2025 | USNA
Annual Financial Statements USANA Health Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
931 M | 1.18 B | 2.14 B | - | 1.52 B | 2.82 B | 1.87 B | 1.73 B | 1.38 B | - | 841 M | 551 M | 605 M |
Shares |
19.2 M | 19.3 M | 21.2 M | - | 22.8 M | 24.6 M | 24.7 M | 26.4 M | 27.4 M | - | 28.4 M | 29.8 M | 31.9 M |
Historical Prices |
48.3 | 61.1 | 101 | 77.1 | 78.5 | 118 | 74 | 61.2 | 63.9 | 51.3 | 37.8 | 16.5 | 15.2 |
Net Income |
63.8 M | 69.4 M | 125 M | - | 101 M | 126 M | 62.5 M | 94.7 M | 76.6 M | - | 79 M | 66.4 M | 45.7 M |
Revenue |
921 M | 999 M | 1.13 B | - | 1.06 B | 1.19 B | 1.05 B | 918 M | 790 M | - | 718 M | 649 M | 518 M |
Cost of Revenue |
177 M | 194 M | 209 M | - | 188 M | 201 M | 179 M | 180 M | - | - | - | - | - |
Gross Profit |
744 M | 805 M | 926 M | - | 873 M | 989 M | 868 M | 759 M | 650 M | - | 591 M | 533 M | 422 M |
Operating Income |
93.1 M | 108 M | 176 M | - | 146 M | 188 M | 133 M | 139 M | 116 M | - | 117 M | 98.2 M | 77.3 M |
Interest Expense |
262 K | 192 K | 507 K | - | 66 K | 36 K | 46 K | 444 K | 129 K | - | 1 K | 20 K | 9 K |
EBITDA |
106 M | 121 M | 190 M | - | 161 M | 205 M | 149 M | 152 M | 125 M | - | 126 M | 107 M | 76.1 M |
Operating Expenses |
651 M | 697 M | 749 M | - | 727 M | 800 M | 735 M | 617 M | 534 M | - | 474 M | 435 M | 354 M |
General and Administrative Expenses |
257 M | 262 M | 261 M | - | 717 M | 791 M | 726 M | 611 M | 528 M | - | 469 M | 430 M | 354 M |
All numbers in USD currency
Quarterly Income Statement USANA Health Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18.3 M | 18.5 M | 19 M | 19.1 M | 19.1 M | 19.1 M | 19.2 M | 19.1 M | 19.2 M | 19.3 M | 19.3 M | 19.2 M | 19.2 M | 19.2 M | 19.4 M | 21 M | 20 M | 20.2 M | 20.9 M | - | 21 M | 21 M | 21.5 M | 21.7 M | 22.2 M | 23.2 M | 23.5 M | 23.6 M | 24.3 M | 24.2 M | 24.1 M | 24 M | 24.3 M | 24.6 M | 24.5 M | 24.5 M | 24.2 M | 24 M | 24.2 M | 12.6 M | 12.9 M | 12.7 M | 12.6 M | - | 12.9 M | 13.8 M | 13.9 M | 13.9 M | 13.8 M | 13.5 M | 13.6 M | 13.8 M | 14.4 M | 14.7 M | 15 M | 14.9 M | 15 M | 15.5 M | 15.9 M |
Net Income |
-6.52 M | 9.66 M | 9.4 M | - | 10.6 M | 10.4 M | 16.5 M | - | 11.3 M | 17.3 M | 18.4 M | - | 14.9 M | 19.2 M | 22.5 M | - | 27.3 M | 38.2 M | 30.6 M | - | 30.5 M | 28 M | 26.6 M | 30.8 M | 24.2 M | 21.4 M | 24.2 M | 32.3 M | 31 M | 33.9 M | 28.9 M | -5.85 M | 23.8 M | 23.3 M | 21.4 M | 21.9 M | 30.1 M | 25.8 M | 22.3 M | 21.3 M | 25.6 M | 25.4 M | 19.7 M | - | 19.5 M | 19.3 M | 16.5 M | 20.3 M | 16.8 M | 24.2 M | 17.8 M | 18.4 M | 17.5 M | 16.7 M | 13.8 M | 13.2 M | 12.4 M | 13.9 M | 11.4 M |
Revenue |
214 M | 236 M | 250 M | - | 200 M | 213 M | 228 M | - | 213 M | 238 M | 248 M | - | 233 M | 264 M | 273 M | - | 274 M | 337 M | 308 M | - | 299 M | 259 M | 267 M | 271 M | 261 M | 256 M | 273 M | 299 M | 297 M | 301 M | 292 M | 273 M | 262 M | 257 M | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
48.8 M | 50.2 M | 52.4 M | - | 39.3 M | 40.3 M | 43.1 M | - | 42.5 M | 43.3 M | 48.5 M | - | 46.6 M | 49.5 M | 51.4 M | - | 50.7 M | 57 M | 57.7 M | - | 56.4 M | 47.7 M | 46.1 M | - | 47.8 M | 46.5 M | 45.9 M | - | 51.9 M | 50 M | 49.4 M | - | 47.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
165 M | 186 M | 197 M | - | 161 M | 173 M | 185 M | - | 171 M | 195 M | 200 M | - | 187 M | 215 M | 221 M | - | 224 M | 280 M | 250 M | - | 242 M | 211 M | 221 M | 224 M | 213 M | 210 M | 227 M | 250 M | 245 M | 251 M | 243 M | 227 M | 215 M | 213 M | 213 M | 207 M | 209 M | 213 M | 198 M | 190 M | 192 M | 193 M | 181 M | - | 157 M | 153 M | 149 M | 152 M | 142 M | 157 M | 139 M | 138 M | 135 M | 133 M | 127 M | 121 M | 118 M | 123 M | 118 M |
Operating Income |
1.22 M | 16.7 M | 15.7 M | - | 15.6 M | 17.8 M | 24.7 M | - | 17.6 M | 24.4 M | 26.8 M | - | 22.6 M | 29.4 M | 33.1 M | - | 40.8 M | 53.7 M | 44.2 M | - | 45.4 M | 39.6 M | 39 M | - | 35.5 M | 31.2 M | 35 M | - | 45.5 M | 51.1 M | 43.1 M | - | 31.4 M | 32.4 M | 32.9 M | - | 35.8 M | 37.4 M | 33.5 M | - | 38 M | 38.8 M | 29.8 M | - | 29.3 M | 29.1 M | 25.1 M | - | 24.7 M | 36.5 M | 26.6 M | - | 24.1 M | 25.2 M | 20.9 M | - | 18.8 M | 21.2 M | 17.2 M |
Interest Expense |
41 K | 1.74 M | 756 K | - | -86 K | -349 K | -186 K | - | 234 K | 229 K | 31 K | - | 32 K | 96 K | 32 K | - | 18 K | 16 K | 5 K | - | 1.38 M | 217 K | 21 K | - | 22 K | 10 K | 12 K | - | 8 K | 9 K | 10 K | - | 10 K | 11 K | 10 K | - | 46 K | 176 K | 202 K | - | 4 K | 7 K | 14 K | - | 5 K | 6 K | 6 K | - | -43 K | -164 K | -104 K | - | 11 K | -293 K | 94 K | - | 1 K | 2 K | 6 K |
EBITDA |
9.14 M | 24.5 M | 24 M | - | 19.2 M | 21.7 M | 27.8 M | - | - | - | 30.1 M | - | 32.7 M | 36 M | 36.3 M | - | 50.5 M | 60.2 M | 47.4 M | - | 45.4 M | 39.6 M | 42.5 M | - | 46.6 M | 38.8 M | 38.9 M | - | 58.2 M | 59.8 M | 47.7 M | - | 43.2 M | 40 M | 36.4 M | - | 45.8 M | 44.2 M | 37 M | - | 45.2 M | 43.4 M | 32.1 M | - | 35.9 M | 33.5 M | 27.3 M | - | 31.6 M | 41.1 M | 28.9 M | - | 30.7 M | 29.6 M | 23.1 M | - | 25.1 M | 25.4 M | 19.4 M |
Operating Expenses |
164 M | 169 M | 181 M | - | 145 M | 155 M | 160 M | - | 153 M | 170 M | 173 M | - | 164 M | 186 M | 188 M | - | 183 M | 226 M | 206 M | - | 197 M | 172 M | 182 M | - | 177 M | 178 M | 192 M | - | 199 M | 200 M | 199 M | - | 183 M | 181 M | 180 M | - | 173 M | 175 M | 164 M | - | 154 M | 154 M | 151 M | - | 128 M | 124 M | 123 M | - | 118 M | 121 M | 112 M | - | 111 M | 108 M | 106 M | - | 99.5 M | 102 M | 101 M |
General and Administrative Expenses |
85.9 M | 81.9 M | 91.4 M | - | 61.3 M | 64.3 M | 64.3 M | - | 63.3 M | 68.1 M | 66.9 M | - | 66 M | 66.4 M | 68.8 M | - | 66.6 M | 72.2 M | 71.6 M | - | 65.7 M | 60.9 M | 65.5 M | - | 66.3 M | 66.9 M | 69.6 M | - | 69.1 M | 67.5 M | 70.1 M | - | 67.3 M | 62.4 M | 64 M | - | 60.6 M | 59.8 M | 56.6 M | - | 52.8 M | 52.5 M | 49.9 M | - | 45.5 M | 43.2 M | 44.6 M | - | 41.1 M | 43 M | 42.4 M | - | 40.3 M | 36.8 M | 38 M | - | 33.4 M | 33.8 M | 35.9 M |
All numbers in USD currency
Main types of financial statements USANA Health Sciences USNAFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting USANA Health Sciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Household products industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Natura &Co Holding S.A.
NTCO
|
- | - | $ 9.02 B | - | |
|
Colgate-Palmolive Company
CL
|
$ 78.29 | 1.35 % | $ 64.1 B | ||
|
The Clorox Company
CLX
|
$ 103.89 | 1.03 % | $ 12.8 B | ||
|
Dogness (International) Corporation
DOGZ
|
$ 10.64 | -2.35 % | $ 359 M | ||
|
Coty
COTY
|
$ 3.22 | -3.59 % | $ 2.8 B | ||
|
LifeVantage Corporation
LFVN
|
$ 6.51 | -0.15 % | $ 79.8 M | ||
|
Acme United Corporation
ACU
|
$ 40.13 | 3.24 % | $ 149 M | ||
|
The Estée Lauder Companies
EL
|
$ 104.12 | -1.36 % | $ 37.5 B | ||
|
e.l.f. Beauty
ELF
|
$ 76.44 | -1.98 % | $ 4.18 B | ||
|
Nature's Sunshine Products
NATR
|
$ 22.7 | 2.39 % | $ 433 M | ||
|
Church & Dwight Co.
CHD
|
$ 84.59 | 1.22 % | $ 20.7 B | ||
|
Kimberly-Clark Corporation
KMB
|
$ 103.21 | -0.23 % | $ 34.6 B | ||
|
Nu Skin Enterprises
NUS
|
$ 10.63 | 1.43 % | $ 528 M | ||
|
The Procter & Gamble Company
PG
|
$ 142.78 | 1.44 % | $ 336 B | ||
|
Revlon
REV
|
- | -4.41 % | $ 212 M | ||
|
Helen of Troy Limited
HELE
|
$ 21.1 | -3.92 % | $ 486 M | ||
|
Hims & Hers Health
HIMS
|
$ 37.08 | -1.83 % | $ 8.01 B | ||
|
Edgewell Personal Care Company
EPC
|
$ 17.49 | -0.14 % | $ 869 M | ||
|
Inter Parfums
IPAR
|
$ 84.22 | 1.7 % | $ 2.69 B | ||
|
Spectrum Brands Holdings
SPB
|
$ 61.19 | -1.7 % | $ 1.57 B | ||
|
United-Guardian
UG
|
$ 6.0 | -0.01 % | $ 27.6 M | ||
|
Mannatech, Incorporated
MTEX
|
$ 8.65 | -2.15 % | $ 16.1 M | ||
|
Newell Brands
NWL
|
$ 3.81 | -1.68 % | $ 1.58 B | ||
|
Unilever PLC
UL
|
$ 64.84 | 0.03 % | $ 132 B |